LT3906927T - Dalinių dopamino d3 agonistų naudojimas centrinės nervų sistemos sutrikimams gydyti - Google Patents
Dalinių dopamino d3 agonistų naudojimas centrinės nervų sistemos sutrikimams gydytiInfo
- Publication number
- LT3906927T LT3906927T LTEP20305429.1T LT20305429T LT3906927T LT 3906927 T LT3906927 T LT 3906927T LT 20305429 T LT20305429 T LT 20305429T LT 3906927 T LT3906927 T LT 3906927T
- Authority
- LT
- Lithuania
- Prior art keywords
- dopamine
- treatment
- nervous system
- central nervous
- system disorders
- Prior art date
Links
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 title 2
- 208000015114 central nervous system disease Diseases 0.000 title 1
- 229960003638 dopamine Drugs 0.000 title 1
- 239000004031 partial agonist Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20305429.1A EP3906927B1 (en) | 2020-05-04 | 2020-05-04 | Use of dopamine d3 partial agonists for treating central nervous system disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT3906927T true LT3906927T (lt) | 2022-08-10 |
Family
ID=70802820
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEP20305429.1T LT3906927T (lt) | 2020-05-04 | 2020-05-04 | Dalinių dopamino d3 agonistų naudojimas centrinės nervų sistemos sutrikimams gydyti |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20230165852A1 (lt) |
| EP (2) | EP3906927B1 (lt) |
| JP (2) | JP2023523862A (lt) |
| KR (1) | KR20230005860A (lt) |
| CN (1) | CN115715195A (lt) |
| AU (1) | AU2021267681A1 (lt) |
| BR (1) | BR112022022317A2 (lt) |
| CA (1) | CA3176643A1 (lt) |
| CY (1) | CY1125228T1 (lt) |
| DK (1) | DK3906927T3 (lt) |
| ES (1) | ES2925982T3 (lt) |
| HR (1) | HRP20220739T1 (lt) |
| HU (1) | HUE059092T2 (lt) |
| IL (1) | IL297706A (lt) |
| LT (1) | LT3906927T (lt) |
| PL (1) | PL3906927T3 (lt) |
| PT (1) | PT3906927T (lt) |
| RS (1) | RS63302B1 (lt) |
| SI (1) | SI3906927T1 (lt) |
| SM (1) | SMT202200332T1 (lt) |
| WO (1) | WO2021224235A1 (lt) |
| ZA (1) | ZA202211589B (lt) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025082974A1 (en) * | 2023-10-16 | 2025-04-24 | Bioprojet Pharma | New formulations of pitolisant and methods of use |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19938823A1 (de) * | 1999-08-19 | 2001-02-22 | Boehringer Ingelheim Pharma | Medikamentöse Behandlung des Restless Leg Syndroms |
| CZ20021880A3 (cs) * | 1999-12-10 | 2002-08-14 | Wyeth | Farmaceutický prostředek |
| EP1591455A1 (en) * | 2004-04-29 | 2005-11-02 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Essential tremor diagnostic and treatment |
| WO2007113260A1 (en) * | 2006-04-03 | 2007-10-11 | Glaxo Group Limited | Azabicyclo [3. 1. o] hexyl derivatives as modulators of dopamine d3 receptors |
| ES2434337T3 (es) * | 2006-04-03 | 2013-12-16 | Glaxo Group Limited | Derivados de azabiciclo[3.1.0]hexilo como moduladores de los receptores D3 de la dopamina |
| EP1870405A1 (en) * | 2006-06-22 | 2007-12-26 | Bioprojet | Carbonylated (Aza)cyclohexanes as dopamine D3 receptor ligands |
| MX2017014192A (es) * | 2015-05-07 | 2018-08-01 | Axovant Sciences Gmbh | Composiciones y metodos de tratamiento de una enfermedad neurodegenerativa. |
-
2020
- 2020-05-04 DK DK20305429.1T patent/DK3906927T3/da active
- 2020-05-04 HR HRP20220739TT patent/HRP20220739T1/hr unknown
- 2020-05-04 ES ES20305429T patent/ES2925982T3/es active Active
- 2020-05-04 PL PL20305429.1T patent/PL3906927T3/pl unknown
- 2020-05-04 SI SI202030066T patent/SI3906927T1/sl unknown
- 2020-05-04 PT PT203054291T patent/PT3906927T/pt unknown
- 2020-05-04 EP EP20305429.1A patent/EP3906927B1/en active Active
- 2020-05-04 LT LTEP20305429.1T patent/LT3906927T/lt unknown
- 2020-05-04 SM SM20220332T patent/SMT202200332T1/it unknown
- 2020-05-04 HU HUE20305429A patent/HUE059092T2/hu unknown
- 2020-05-04 RS RS20220566A patent/RS63302B1/sr unknown
-
2021
- 2021-05-04 JP JP2022567115A patent/JP2023523862A/ja active Pending
- 2021-05-04 CA CA3176643A patent/CA3176643A1/en active Pending
- 2021-05-04 CN CN202180032213.0A patent/CN115715195A/zh active Pending
- 2021-05-04 IL IL297706A patent/IL297706A/en unknown
- 2021-05-04 EP EP21722486.4A patent/EP4146214A1/en active Pending
- 2021-05-04 AU AU2021267681A patent/AU2021267681A1/en active Pending
- 2021-05-04 WO PCT/EP2021/061689 patent/WO2021224235A1/en not_active Ceased
- 2021-05-04 BR BR112022022317A patent/BR112022022317A2/pt unknown
- 2021-05-04 KR KR1020227038661A patent/KR20230005860A/ko active Pending
- 2021-05-04 US US17/922,767 patent/US20230165852A1/en active Pending
-
2022
- 2022-06-09 CY CY20221100402T patent/CY1125228T1/el unknown
- 2022-10-24 ZA ZA2022/11589A patent/ZA202211589B/en unknown
-
2025
- 2025-06-18 JP JP2025102427A patent/JP2025120504A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230005860A (ko) | 2023-01-10 |
| SMT202200332T1 (it) | 2022-09-14 |
| IL297706A (en) | 2022-12-01 |
| ES2925982T3 (es) | 2022-10-20 |
| HRP20220739T1 (hr) | 2022-08-19 |
| HUE059092T2 (hu) | 2022-10-28 |
| CY1125228T1 (el) | 2025-03-28 |
| CN115715195A (zh) | 2023-02-24 |
| JP2023523862A (ja) | 2023-06-07 |
| ZA202211589B (en) | 2023-04-26 |
| BR112022022317A2 (pt) | 2022-12-13 |
| DK3906927T3 (da) | 2022-06-20 |
| EP3906927B1 (en) | 2022-05-25 |
| PL3906927T3 (pl) | 2022-07-25 |
| WO2021224235A1 (en) | 2021-11-11 |
| CA3176643A1 (en) | 2021-11-11 |
| EP3906927A1 (en) | 2021-11-10 |
| AU2021267681A1 (en) | 2022-12-01 |
| SI3906927T1 (sl) | 2022-08-31 |
| PT3906927T (pt) | 2022-07-27 |
| EP4146214A1 (en) | 2023-03-15 |
| RS63302B1 (sr) | 2022-07-29 |
| US20230165852A1 (en) | 2023-06-01 |
| JP2025120504A (ja) | 2025-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL295536A (en) | Specific tryptamines for use in the treatment of mood disorders | |
| FR23C1035I2 (fr) | Promédicaments de la carbidopa et l-dopa ainsi que leur utilisation pour traiter la maladie de parkinson | |
| HUE059559T2 (hu) | 5HT agonisták az epilepsziás rendellenességek kezelésére | |
| IL274648A (en) | Promote new catecholamine drugs for use in the treatment of Parkinson's disease | |
| MX2018005694A (es) | 2- (1h-indazol-3-il) -3h-imidazo[4,5-c] piridinas y usos antiinflamatorios de las mismas. | |
| LT3472153T (lt) | Pirimidin-2-ilamino-1h-pirazolai kaip lrrk2 inhibitoriai, skirti naudoti neurodegeneracinių sutrikimų gydyme | |
| SI3377637T1 (sl) | Sestavki za uporabo pri postopkih za zdravljenje ran, motenj in bolezni kože | |
| MX381640B (es) | Metodos y compuestos agonistas de gip. | |
| MX2013006911A (es) | Peliculas sub-linguales. | |
| HUE061761T2 (hu) | Tetrahidropiranil-amino-pirrolopirimidinon felhasználásra BTK-által közvetített zavarok kezelésében | |
| EP3307754A4 (en) | NICOTINAMIDRIBOSIDE AND PTEROSTODY COMPOSITIONS AND METHOD FOR TREATING SKIN DISEASES | |
| PL3197429T3 (pl) | Leczenie skojarzone inhibitorami sglt2 i agonistami dopaminy do profilaktyki zaburzeń metabolicznych u zwierząt koniowatych | |
| MX379318B (es) | Metodos para tratar trastornos de sueño de ritmo circadiano. | |
| IL275349A (en) | Use of hM4Di in the treatment of seizure disorders | |
| IL270900A (en) | Treatment of cutaneous disorders | |
| SG11202103191QA (en) | Benzimidazole derivative for use in the treatment of inflammatory disorders | |
| LT3906927T (lt) | Dalinių dopamino d3 agonistų naudojimas centrinės nervų sistemos sutrikimams gydyti | |
| IL274838A (en) | Use of MIR101 or MIR128 in the treatment of seizure disorders | |
| MA51128A (fr) | Inhibiteurs c5ar destinés à être utilisés dans le traitement de la douleur iatrogène induite par la chimiothérapie | |
| LT3897578T (lt) | Ly3154207 dozavimo režimai gydant dopaminerginius cns sutrikimus | |
| DK3897655T3 (da) | 3beta-(benzyloxy)-17alpha-methyl-pregn-5-en-20-on til anvendelse i behandlingen af kognitive lidelser | |
| PL3727349T3 (pl) | Nanocząstki do zastosowania do leczenia zaburzenia neuronalnego | |
| EP3384285A4 (en) | TREATMENT OF FIBROTIC DISEASES | |
| IT201600122310A1 (it) | Composizione per uso nella terapia di alterazioni dell'intestino | |
| EP3310396A4 (en) | THERAPEUTIC NANOFIBER HYDROGELS FOR THE LOCAL TREATMENT OF BRAIN ASSOCIATED DISEASES |